Browsing category:

Patent Expiration 2019


Daptomycin, recognized as the brand name antibiotic Cubicin, has a patent expiration of September 24, 2019. Cubist Pharmaceutical markets Cubicin and they recently released a report revealing surprisingly weak sales. Initially Cubist reported strong sales of Daptomycin for the first quarter of 2013, with an overall rise in their revenues due to this potent antibiotic.[…]

Read More

Used to regulate hormone responses in female patients undergoing infertility treatment, Cetrorelix, is also known as the brand name Cetrotide. On April 17, 2013 Aeterna Zentaris announced the transfer of the manufacturing rights of this powerhouse product to Merck Serono. With the patent for Cetrotide set to expire on April 23, 2019, this transfer of[…]

Read More

A recently published study in the American Journal of Kidney Diseases offered a sobering look at the incidence and seriousness of Hyponatremia among hemodialysis patients. Published on April 13, 2013 the aforementioned study focused on patients on hemodialysis and how the condition of Hyponatremia significantly affected their health and mortality risk. Patients who were diagnosed[…]

Read More

The biopharmaceutical company Rockwell Medical is anxiously awaiting approval from the FDA for its injectable Vitamin D drug, Calcitriol CAS# 32222-06-3. This promising new indication approval was submitted in April of 2013, with the goal of better managing hypocalcemia in patients who experience chronic renal dialysis. As an active injectable treatment known as the brand[…]

Read More

On June 4, 2013 Aqua Pharmaceuticals announced its acquisition of the brand name foam of Desonide, coined Verdeso, from Stiefel Pharmaceuticals. This announcement was extremely positive for Aqua Pharmaceuticals, as they already hold a thriving lineup of dermatologic products, such as Fluoroplex and Cordran. The addition of Verdeso, a foam formulation of Desonide, has filled[…]

Read More

Diclofenac Potassium CAS# 15307-81-0, also known as the brand name Zipsor, netted an astounding three million dollars in sales for the first quarter of 2013. Depomed Incorporated, who markets the NSAID, recently reported their better than expected financials regarding this efficacious treatment for arthritis and pain. The patent for Zipsor expires on July 15, 2019,[…]

Read More

The first topical steroid, Difluprednate, known as the brand name Durezol, continues to prove itself year after year. As a difluorinated derivative of prednisolone, Difluprednate has been indicated to treat both eye pain and inflammation after surgery, as well as anterior uveitis. A recent clinical trial published on June 18, 2013 indicated success for participants[…]

Read More

Exciting results were revealed in Mid-March of 2013 when the REMINDER trial touted the success of Eplerenone for treating acute ST-Segment Elevation Myocardial Infarction, also known as STEMI. The results from this study were presented at the 62nd Annual Scientific Session of the American College of Cardiology, by Pfizer, who markets Inspra which is the[…]

Read More

Ethinyl Estradiol CAS# 57-63-6 Ethinyl Estradiol, CAS number 57-63-6 and Norgestimate, CAS number 35189-28-7, are both integral components in the blockbuster birth control pill Ortho Tri-Cyclen Lo. Mylan and Janssen, who market Ortho Tri-Cyclen Lo, reported an astounding 425.5 million dollars in sales for the United States for the 2012 year. With the patent for[…]

Read More

Ranolazine shined at the American College of Cardiology’s 62nd Annual Scientific Session in Mid-March 2013 when data from a phase 4 study, coined TERISA revealed positive findings. Known as the brand name Ranexa, Ranolazine is an efficacious treatment for chronic angina. The TERISA study, standing for Type 2 Diabetes Evaluation of Ranolazine In Subjects With[…]

Read More